LL-37 Peptide Protocol Guide: Dosage, Reconstitution & Immune Support Breakdown

LL-37

LL-37 is a naturally occurring antimicrobial peptide produced as part of the body's innate immune defense system. Research has studied its antimicrobial activity, immune signaling, inflammation regulation, and role in wound healing. Human clinical research has primarily evaluated locally applied LL-37 for chronic wounds; standardized human subcutaneous dosing has not been established.

How It Works

Antimicrobial Activity ↑ → Immune Modulation ↑ → Tissue Repair ↑ → Inflammation Regulation

LL-37 can disrupt certain microbial membranes while also influencing immune and inflammatory signaling. Preclinical research also suggests roles in processes involved in wound repair, including cell migration, re-epithelialization, and angiogenesis.

Injectable Research-Use Protocol

5 mg vial + 3.0 mL BAC Water → 1 unit = 16.7 mcg → Gradual Immune + Tissue Support

Gradual Research-Use Approach

5 mg vial reconstituted with 3.0 mL bacteriostatic water

1 unit = 16.7 mcg

Days 1–3

Starting Dose

Dose50 mcg

Units3 units

Volume0.03 mL

Days 4–10

Build

Dose100 mcg

Units6 units

Volume0.06 mL

Days 11–21

Higher Range

Dose150 mcg

Units9 units

Volume0.09 mL

Research Status:
Human LL-37 research has primarily evaluated local or topical application for chronic wounds. A standardized subcutaneous dose, frequency, or cycle length has not been established in controlled human trials. The injectable schedule shown here reflects a research-use framework rather than a clinically validated dosing protocol.

How to Use LL-37 (Cycle, Timing & Injection)

FrequencyOnce daily

TimingMorning or early day

RouteSubcutaneous

Cycle Length2–4 weeks

Use StyleShort-term injectable research-use approach

Timing Considerations

Morning or early day is commonly preferred.

Earlier timing can make it easier to monitor fatigue, immune response shifts, or inflammation changes.

Consistency matters more than exact clock timing.

No clinically established best time of day exists for injectable LL-37. Morning or earlier-day administration is sometimes discussed in research-use protocols, but this reflects practice preference rather than validated clinical evidence

Where to Inject

Subcutaneous administration is discussed in research-use protocols, although standardized human SubQ administration has not been established. Commonly discussed sites include the abdomen and thigh. Local injection near an affected area should not be assumed to provide greater benefit, as comparative human evidence is lacking.

Areas of Research Interest

Innate immune and antimicrobial signaling

Wound-healing and tissue-repair research

Inflammatory signaling and immune-response research

Host-defense and microbiome-related research

Short-term injectable research frameworks

Simple Strategy

Start Low

LL-37 is highly active in immune signaling, so the goal is usually controlled support rather than aggressive dosing.

Short Phase Use

It is most commonly discussed in short 2–4 week support phases, followed by reassessment.

Injectable Research Use vs Human Clinical Research

Injectable Research-Use Framework

Discussed Range 50–150 mcg daily

Route Subcutaneous

Evidence Not established in controlled human trials

Human Clinical Research

Route Studied Local / topical wound application

Frequency Studied Twice weekly

Research Areas Chronic venous leg ulcers + diabetic foot ulcers

Evidence Human trials exist for local application, but do not validate subcutaneous dosing

Reconstitution & Dosing

Reconstitution & Dosing

Vial5 mg

Water3.0 mL

Concentration1.67 mg/mL

Conversion1 unit = 16.7 mcg

Dose Reference

3 units = 50 mcg

6 units = 100 mcg

9 units = 150 mcg

12 units = 200 mcg

Reconstitution Steps

Draw 3.0 mL bacteriostatic water

Inject slowly down the vial wall

Gently swirl, do not shake

Allow full dissolution

Refrigerate at 2–8°C after mixing

Important:

Unit math depends on vial size and water volume. This example uses a 5 mg vial with 3.0 mL added, creating a 1 unit = 16.7 mcg conversion.

Storage & Shelf Life

Storage & Shelf Life

Lyophilized (unmixed)

Refrigerated (2–8°C): ~12–24 months

Frozen (−20°C): up to ~2–3 years

Store sealed, dry, and protected from light

Reconstituted (mixed)

Refrigerated (2–8°C): about 3–4 weeks typical use window

Do not freeze after mixing

Avoid repeated temperature changes

Best Practice

Handling

Keep LL-37 cold, protected from light, and limit unnecessary handling after mixing.

Visual Check

If the solution becomes cloudy, discolored, or contains visible particles, it is safer not to continue using it.

Time Between Cycles

Short Immune Phase → Reassess → Reset → Repeat if Needed

Research-Use Cycle Framework

Cycle Length2–4 weeks

Time Off2–4 weeks

Use StyleShort targeted support phase

Why take a break?
The 2–4 week break shown here is a research-use framework rather than a clinically established requirement. Reassessment between short injectable research phases can help avoid assuming that continuous exposure is necessary.

Example Research-Use Structures

Option 12–3 weeks, then reassess

Short-duration research framework

Option 23–4 weeks, then reassess

Longer research-use framework

Option 3Use only within a defined research period

Avoid assuming continuous use is necessary

When to Stop Sooner

Temporary inflammation increase becomes uncomfortable

Fatigue or immune response shifts become noticeable

Injection site irritation becomes persistent

Continued use extends beyond the defined research-use period

Monitoring During Use

Immune response and symptoms

Skin or wound healing progress

Inflammation levels

Injection site tolerance

Potential / Studied Effects

Antimicrobial activity demonstrated in laboratory research

Studied for immune and inflammatory signaling

Human topical studies have evaluated LL-37 for chronic wound healing

Preclinical research suggests roles in tissue-repair and angiogenic pathways

Potential Side Effects

Injection-site irritation or sensitivity may occur with injectable use

LL-37 can influence immune and inflammatory signaling

Human safety data for subcutaneous LL-37 remain very limited

Long-term safety of repeated systemic or injectable use has not been established

Important Notes

Human LL-37 research has primarily evaluated local or topical wound application rather than subcutaneous administration.

No standardized human subcutaneous dose, frequency, or cycle length has been established.

Injectable protocols discussed on this page represent research-use frameworks rather than validated clinical dosing guidelines.

Evidence from topical wound studies should not automatically be extrapolated to systemic or injectable use.

Important Disclaimer

LL-37 is an investigational peptide and is not FDA-approved. This content is for educational and research purposes only.

Research & References

Primary Research

• Dürr UH, Sudheendra US, Ramamoorthy A. LL-37, the Only Human Member of the Cathelicidin Family of Antimicrobial Peptides. Biochimica et Biophysica Acta (BBA) – Biomembranes. 2006.
• Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL-37, a Cathelin-Associated Antimicrobial Peptide of Human Neutrophils. Antimicrobial Agents and Chemotherapy. 1998.
• Keshri AK, Rawat SS, Chaudhary A, et al. LL-37, the Master Antimicrobial Peptide, its Multifaceted Role from Combating Infections to Cancer Immunity. International Journal of Antimicrobial Agents. 2025.

Research Note: LL-37 is one of the best-studied endogenous antimicrobial peptides in humans, with decades of laboratory research supporting its role in innate immunity and antimicrobial defense. Dosing protocols for LL-37 as a research or investigational peptide are not standardized by clinical trials in humans.

LL-37 Guide → Browse All Peptides →